Malignant melanoma (MM) is a highly aggressive and deadly form of skin cancer, primarily caused by recurrence and metastasis. Therefore, it is crucial to investigate the regulatory mechanisms underlying melanoma recurrence and metastasis. Our study has identified a potential targeted regulatory relationship between LINC02202, miR‐526b‐3p and XBP1 in malignant melanoma. Through the regulation of the miR‐526b‐3p/XBP1 signalling pathway, LINC02202 may play a role in tumour progression and immune infiltration and inhibiting the expression of LINC02202 can increase the efficacy of immunotherapy for melanoma. Our findings shed light on the impact of LINC02202/XBP1 on the phenotype and function of malignant melanoma cells. Furthermore, this study provides a theoretical foundation for the development of novel immunotherapy strategies for malignant melanoma.

中文翻译：

---

黑色素瘤中 LINC02202/XBP1 轴的转录组学分析：对药物靶向和 PD-1 单克隆抗体功效的影响

恶性黑色素瘤 (MM) 是一种高度侵袭性和致命性的皮肤癌，主要由复发和转移引起。因此，研究黑色素瘤复发和转移的调控机制至关重要。我们的研究发现了恶性黑色素瘤中 LINC02202、miR-526b-3p 和 XBP1 之间潜在的靶向调控关系。通过调节miR-526b-3p/XBP1信号通路，LINC02202可能在肿瘤进展和免疫浸润中发挥作用，抑制LINC02202的表达可以提高黑色素瘤免疫治疗的疗效。我们的研究结果揭示了 LINC02202/XBP1 对恶性黑色素瘤细胞表型和功能的影响。此外，该研究为恶性黑色素瘤新型免疫治疗策略的开发提供了理论基础。